This 2013 study assessed the impact of 600 mg/day alpha-lipoic acid (ALA) supplementation on cognitive function in 126 Alzheimer’s disease (AD) patients, divided into two groups based on the presence (Group A) or absence (Group B) of diabetes mellitus (DM). Cognitive assessments included MMSE, ADAS-Cog, CIBIC, CDR, and ADFACS. Results
This open-label study evaluated the long-term effects of daily 600 mg alpha-lipoic acid (ALA) supplementation in 43 patients with mild to moderate Alzheimer’s disease (AD) over a 48-month period. All participants were concurrently receiving standard acetylcholinesterase inhibitor therapy. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the
This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and tolerability of choline alfoscerate (CA) in treating cognitive impairment in patients with mild to moderate Alzheimer’s disease (AD). A total of 261 patients were randomized to receive either CA (400 mg capsules) or placebo, three times daily for 180 days.
This open-label pilot study assessed the potential of alpha-lipoic acid (ALA) as an adjunctive treatment for Alzheimer’s disease (AD). Nine patients with AD or related dementias received 600 mg of ALA daily alongside standard acetylcholinesterase inhibitor therapy over an average of 337 days. Cognitive performance, measured by MMSE and ADAS-Cog,
This 2006 observational study examined whether lithium use is associated with cognitive benefits in older adults. Researchers reviewed clinical records of 1,423 psychiatric outpatients aged 60 and above, comparing those with current or past lithium prescriptions to age- and gender-matched controls without lithium exposure. Although there was no significant difference
This study evaluates the cognitive-enhancing effects of two phosphatidylcholine derivatives: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPhtCho) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPhtCho). In scopolamine-induced amnesic rats, oral administration of DLPhtCho (5 mg/kg) or POPhtCho (5 mg/kg) individually, and especially their combination, significantly reduced acquisition and retention latencies in the Morris water maze test. The combined treatment outperformed
This study investigates the effects of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPhtCho) on cognitive function. In rat hippocampal slices, POPhtCho (1 μM) enhanced long-term depression (LTD), a synaptic plasticity mechanism associated with learning and memory, by reducing the expression of the AMPA receptor subunit GluR1 on the plasma membrane. In vivo, oral administration of
This cohort study examined how genetic variations in glutathione S-transferase (GST) enzymes—specifically the GSTP1 Val105 and GSTM1 deletion polymorphisms—modify the relationship between cumulative lead exposure and cognitive function in older men from the Normative Aging Study. Using bone lead levels measured by K-shell X-ray fluorescence and Mini-Mental State Exam (MMSE)
